GO:0086014 atrial cardiac muscle cell action potential: Electrophysiology, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0086014 describes the action potential that occurs specifically in atrial cardiac muscle cells, a biological process distinct from ventricular action potentials.
• Atrial action potentials are shaped by a unique complement of ion channels, including CaV1.2, NaV1.5, Kv4.3, and Kir2.1, whose expression and regulation determine atrial excitability and refractoriness.
• Human induced pluripotent stem cell-derived atrial cardiomyocytes (hiPSC-aCMs) provide a tractable model to study atrial action potential remodeling and antiarrhythmic drug responses.
• Atrial fibrillation is associated with electrical remodeling of the atrial action potential, including changes in ion channel expression and mitochondrial dysfunction.
• Genes such as PITX2, ATRNL1, and inflammatory mediators like IL-1β modulate atrial electrophysiology and susceptibility to atrial fibrillation.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of candidate genes in atrial action potential regulation and arrhythmia mechanisms.
Description
The atrial cardiac muscle cell action potential (GO:0086014) is the electrical impulse that triggers contraction in the atria of the heart. It is a specialized biological process that differs from ventricular action potentials in duration, ion channel composition, and pharmacological response. Understanding this process is essential for researchers studying cardiac electrophysiology, atrial arrhythmias, and the development of atrial-selective therapeutics. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is closely linked to electrical remodeling of the atrial action potential, making GO:0086014 a central node in AF research. Recent advances in single-nuclei profiling and stem cell-derived atrial engineered tissue have further highlighted the molecular players that shape atrial action potentials. This article synthesizes current knowledge on the definition, mechanisms, genes, and research methods relevant to GO:0086014, with a focus on experimentally validated findings from the PubMed literature.
atrial cardiac muscle cell action potential At A Glance
| GO ID | GO:0086014 |
|---|---|
| GO term | atrial cardiac muscle cell action potential |
| Ontology | biological_process |
| Synonym | none |
| Major function | Generation and propagation of electrical impulses in atrial cardiac muscle cells, initiating atrial contraction |
| Related cell type | Atrial cardiomyocyte |
| Key ion channels | CaV1.2, NaV1.5, Kv4.3, Kir2.1, HCN4 |
| Associated disease | Atrial fibrillation, atrial arrhythmias |
| Research models | hiPSC-derived atrial cardiomyocytes, heterocellular atrial engineered tissue, animal models |
What Is GO:0086014?
GO:0086014 is defined as an action potential that occurs in an atrial cardiac muscle cell. In other words, it is the sequence of rapid changes in membrane potential that enables atrial cardiomyocytes to generate and propagate electrical signals, ultimately leading to atrial contraction. This process is distinct from action potentials in other cardiac cell types, such as ventricular myocytes or nodal cells, due to differences in ion channel expression and regulation.
Why Is atrial cardiac muscle cell action potential Important in Cell Biology?
The atrial cardiac muscle cell action potential is fundamental to normal heart function, as it governs the timing and coordination of atrial contraction. Dysregulation of this process leads to atrial arrhythmias, most notably atrial fibrillation, which affects millions worldwide and is associated with significant morbidity and mortality. Studying GO:0086014 helps researchers identify molecular targets for antiarrhythmic therapy and understand how genetic and environmental factors contribute to atrial electrical remodeling.
• Defines the electrical phenotype of atrial cardiomyocytes, distinct from ventricular cells.
• Underlies the initiation and maintenance of atrial contraction and cardiac output.
• Its remodeling is a hallmark of atrial fibrillation, the most common arrhythmia.
• Provides a target for atrial-selective antiarrhythmic drugs to avoid ventricular side effects.
• Involved in inflammatory and metabolic pathways that modulate atrial electrophysiology.
• Genetic variants in ion channel and regulatory genes alter atrial action potential properties.
• Stem cell-derived atrial cardiomyocytes enable patient-specific modeling of atrial electrophysiology.
• CRISPR screening can identify novel regulators of atrial action potential duration and morphology.
• Mitochondrial dysfunction and oxidative stress impact atrial action potential via metabolic remodeling.
• Autoimmune and inflammatory signals can modulate atrial electrical function.
What Happens During atrial cardiac muscle cell action potential?
Phase 0: Rapid Depolarization
In simple terms: The cell rapidly becomes positively charged due to sodium influx.
In atrial cardiac muscle cells, the action potential begins with a rapid upstroke (phase 0) driven by the opening of voltage-gated sodium channels, primarily NaV1.5 (encoded by SCN5A). This influx of sodium ions depolarizes the membrane potential from approximately -80 mV to +20 mV. The availability and gating properties of NaV1.5 determine the excitability and conduction velocity of atrial tissue.
Phase 1: Early Repolarization
In simple terms: A brief partial return toward negative charge occurs as potassium ions leave the cell.
Following peak depolarization, transient outward potassium currents (Ito) mediated by Kv4.3 (KCND3) channels contribute to early repolarization (phase 1). This phase is more prominent in atrial than ventricular myocytes and influences the plateau potential and action potential duration.
Phase 2: Plateau
In simple terms: A balance of calcium entry and potassium exit maintains a prolonged positive charge.
The plateau phase (phase 2) is sustained by a delicate balance between inward calcium current through L-type calcium channels (CaV1.2, CACNA1C) and outward potassium currents. In atrial cells, the ultra-rapid delayed rectifier potassium current (IKur) carried by Kv1.5 (KCNA5) is a major contributor to repolarization and is a target for atrial-selective antiarrhythmic drugs.
Phase 3: Repolarization
In simple terms: The cell returns to its negative resting state as potassium ions continue to exit.
Phase 3 repolarization is driven by the inactivation of calcium channels and the activation of various potassium currents, including the rapid and slow delayed rectifier currents (IKr and IKs) and the inward rectifier current (IK1) via Kir2.1 (KCNJ2). The duration of the action potential is largely determined by the interplay of these currents and is subject to modulation by autonomic and metabolic factors.
Phase 4: Resting Potential
In simple terms: The cell stays at a stable negative charge until the next electrical signal.
In atrial cardiomyocytes, the resting membrane potential (phase 4) is maintained primarily by the inward rectifier potassium current (IK1) through Kir2.1 channels. Unlike pacemaker cells, atrial myocytes do not spontaneously depolarize, but their resting potential can be influenced by the funny current (If) carried by HCN channels under certain conditions.
Key Genes Involved in GO:0086014 atrial cardiac muscle cell action potential
The following genes encode ion channels, transporters, and regulatory proteins that are critical for the atrial cardiac muscle cell action potential.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCN5A | Encodes NaV1.5 sodium channel; mediates phase 0 depolarization | Mutations linked to atrial fibrillation and Brugada syndrome; target for antiarrhythmic drugs |
| CACNA1C | Encodes CaV1.2 L-type calcium channel; maintains plateau phase | Modulates action potential duration; involved in atrial arrhythmias |
| KCND3 | Encodes Kv4.3; mediates transient outward potassium current (Ito) | Contributes to early repolarization; atrial-specific expression |
| KCNA5 | Encodes Kv1.5; mediates ultra-rapid delayed rectifier current (IKur) | Atrial-selective target for antiarrhythmic therapy |
| KCNJ2 | Encodes Kir2.1; maintains resting membrane potential | Dysfunction leads to Andersen-Tawil syndrome and atrial arrhythmias |
| HCN4 | Encodes HCN4; contributes to funny current (If) | Involved in atrial pacemaking and arrhythmogenesis |
| PITX2 | Transcription factor regulating atrial ion channel expression | Deficiency causes mitochondrial dysfunction and atrial fibrillation susceptibility |
| ATRNL1 | Attractin-like 1; involved in atrial fibrillation pathogenesis | Identified by single-nuclei profiling as a novel AF gene |
| IL1B | Pro-inflammatory cytokine; modulates atrial electrophysiology | Enhances AF susceptibility via macrophage activation |
| CASP1 | Caspase-1; mediates inflammation and pyroptosis | Linked to IL-1β-driven atrial remodeling |
| STING1 | Stimulator of interferon genes; mediates mitochondrial damage response | Activated in obesity-mediated atrial fibrillation |
| KCNH2 | Encodes Kv11.1; mediates rapid delayed rectifier current (IKr) | Mutations cause long QT syndrome and atrial arrhythmias |
| KCNQ1 | Encodes Kv7.1; mediates slow delayed rectifier current (IKs) | Associated with atrial fibrillation and short QT syndrome |
| SCN1B | Beta subunit of sodium channel; modulates NaV1.5 gating | Mutations linked to Brugada syndrome and atrial arrhythmias |
| GJA1 | Connexin 43; mediates gap junctional coupling | Altered expression in atrial fibrillation |
| GJA5 | Connexin 40; atrial-specific gap junction protein | Mutations associated with atrial fibrillation |
| MYH6 | Atrial myosin heavy chain; contractile protein | Mutations linked to atrial septal defects and arrhythmias |
| NPPA | Atrial natriuretic peptide; regulates blood pressure and volume | Biomarker of atrial stretch and AF |
How Is atrial cardiac muscle cell action potential Regulated?
The atrial cardiac muscle cell action potential is regulated by multiple signaling pathways and transcriptional programs. PITX2, a homeodomain transcription factor, controls the expression of ion channel genes and mitochondrial function in atrial cardiomyocytes; its deficiency leads to mitochondrial dysfunction and increased susceptibility to atrial fibrillation. Inflammatory signaling, particularly via IL-1β and caspase-1, can modulate atrial electrophysiology by affecting ion channel function and promoting fibrosis. Metabolic stress, such as obesity-induced mitochondrial damage, activates STING and contributes to atrial electrical remodeling. Additionally, autoantibodies produced by B cells can promote atrial fibrillation through effects on atrial myocytes. These regulatory mechanisms highlight the integration of genetic, inflammatory, and metabolic cues in shaping the atrial action potential.
atrial cardiac muscle cell action potential and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PITX2 | Atrial fibrillation, mitochondrial dysfunction | PITX2 knockout hiPSC-derived atrial cardiomyocytes |
| ATRNL1 | Atrial fibrillation | ATRNL1 knockout or overexpression in hiPSC-aCMs |
| IL1B | Atrial fibrillation, inflammation | IL-1β overexpression or knockout in mouse atrial tissue |
| STING1 | Obesity-mediated atrial fibrillation | STING1 knockout in obese mouse models |
| SCN5A | Atrial fibrillation, Brugada syndrome | SCN5A point mutation knock-in hiPSC-aCMs |
Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is strongly associated with electrical remodeling of the atrial action potential. Studies using human induced pluripotent stem cell-derived atrial cardiomyocytes have revealed that AF-associated electrical remodeling includes changes in ion channel expression and action potential duration, providing a platform for antiarrhythmic drug development. Single-nuclei profiling has identified ATRNL1 as a novel gene involved in AF pathogenesis, underscoring the genetic complexity of the disease. Inflammatory mediators such as IL-1β enhance AF susceptibility by acting through resident macrophages and promoting caspase-1 expression. Obesity-mediated AF involves mitochondrial damage and STING activation, linking metabolic stress to atrial electrical dysfunction.
Mitochondrial Dysfunction and Atrial Arrhythmias
PITX2 deficiency leads to atrial mitochondrial dysfunction, which impairs energy supply and contributes to atrial arrhythmogenesis. Mitochondrial damage also mediates STING activation in obesity-mediated AF, suggesting that mitochondrial quality control is critical for maintaining normal atrial action potentials. These findings highlight the interplay between metabolic pathways and atrial electrophysiology.
Inflammation and Autoimmunity in Atrial Fibrillation
B cells promote atrial fibrillation via autoantibodies, indicating an autoimmune component in some AF cases. Colitis-induced atrial electrophysiological remodeling demonstrates that systemic inflammation can affect atrial action potentials. IL-1β signaling through macrophages and caspase-1 represents a key inflammatory pathway that modulates atrial electrical function.
From atrial cardiac muscle cell action potential-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene alter atrial action potential duration? | CRISPR knockout in hiPSC-derived atrial cardiomyocytes |
| Does a specific point mutation in SCN5A affect atrial excitability? | Point mutation knock-in in hiPSC-aCMs |
| Can overexpression of PITX2 rescue mitochondrial dysfunction? | PITX2 overexpression in PITX2-knockout hiPSC-aCMs |
| What is the role of ATRNL1 in atrial fibrillation? | ATRNL1 knockout and overexpression in hiPSC-aCMs |
| How does IL-1β signaling modulate atrial electrophysiology? | IL-1β knockout or macrophage-specific overexpression in mice |
| Does STING activation mediate obesity-induced atrial remodeling? | STING1 knockout in diet-induced obese mice |
How to Study the atrial cardiac muscle cell action potential Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Action potential duration, ion currents | Characterizing electrical remodeling in hiPSC-aCMs |
| Optical mapping | Action potential propagation and arrhythmia dynamics | Studying heterocellular atrial tissue |
| Single-nuclei RNA-seq | Transcriptomic profiles of atrial cells | Identifying novel AF genes like ATRNL1 |
| CRISPR knockout screening | Gene function in atrial electrophysiology | High-throughput target discovery |
| Calcium imaging | Intracellular calcium transients | Assessing calcium handling in atrial cardiomyocytes |
| Mitochondrial function assays | Mitochondrial membrane potential, ROS | Evaluating metabolic dysfunction in AF |
| Immunofluorescence | Protein localization and expression | Validating ion channel expression in atrial tissue |
| Western blot | Protein expression levels | Quantifying ion channel and signaling proteins |
Patch-Clamp Electrophysiology
Patch-clamp recording is the gold standard for measuring action potentials in atrial cardiomyocytes. It allows precise quantification of action potential duration, resting membrane potential, and ion channel currents. This technique has been used to characterize electrical remodeling in hiPSC-derived atrial cardiomyocytes from AF patients.
Optical Mapping and Voltage-Sensitive Dyes
Optical mapping with voltage-sensitive dyes enables non-invasive recording of action potential propagation in atrial tissue and engineered cardiac tissues. This method is particularly useful for studying heterocellular interactions and arrhythmia mechanisms in stem cell-derived atrial engineered tissue.
Single-Nuclei RNA Sequencing
Single-nuclei RNA sequencing (snRNA-seq) allows transcriptomic profiling of individual atrial cardiomyocytes and other cell types in the heart. This approach identified ATRNL1 as a novel gene associated with atrial fibrillation, demonstrating its power in discovering new regulators of atrial action potentials.
CRISPR Screening and Functional Genomics
CRISPR-based loss-of-function screens can systematically identify genes that regulate atrial action potential properties. Combined with hiPSC-derived atrial cardiomyocytes and high-throughput electrophysiology or calcium imaging, this approach accelerates target discovery for atrial arrhythmias.
How CRISPR Can Be Used to Study GO:0086014 atrial cardiac muscle cell action potential
Knockout
CRISPR knockout of candidate genes in hiPSC-derived atrial cardiomyocytes or animal models allows researchers to determine whether a gene is necessary for normal atrial action potential properties. For example, knockout of PITX2 in hiPSC-aCMs recapitulates mitochondrial dysfunction and electrical remodeling seen in AF. Knockout of ATRNL1 can test its role in atrial fibrillation pathogenesis.
Point Mutation
Point mutation knock-in using CRISPR enables the study of specific genetic variants associated with atrial arrhythmias. For instance, introducing SCN5A mutations linked to Brugada syndrome or AF into hiPSC-aCMs can reveal their effects on sodium current and action potential duration. This approach is valuable for precision medicine and genotype-phenotype correlation.
Knock-in
Large fragment knock-in, such as fluorescent reporters or epitope tags, can be used to visualize ion channel localization and dynamics in atrial cardiomyocytes. Tagging endogenous SCN5A or CACNA1C with GFP allows real-time imaging of channel trafficking and membrane expression.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase the expression of genes of interest to test sufficiency in atrial action potential regulation. Overexpression of PITX2 or ATRNL1 in hiPSC-aCMs can rescue or exacerbate electrical phenotypes, providing causal evidence.
How EDITGENE Supports atrial cardiac muscle cell action potential Research
Researchers studying atrial cardiac muscle cell action potential-related genes often need to determine whether a candidate gene is causally involved in atrial electrophysiology or arrhythmia susceptibility. This requires precise genetic manipulation in relevant cell models, such as hiPSC-derived atrial cardiomyocytes or animal hearts. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for atrial cardiac muscle cell action potential research.
Frequently Asked Questions About atrial cardiac muscle cell action potential
What is GO:0086014?
GO:0086014 is the Gene Ontology term for the action potential that occurs in an atrial cardiac muscle cell, a biological process essential for atrial contraction and heart function.
What genes are involved in atrial cardiac muscle cell action potential?
Key genes include SCN5A, CACNA1C, KCND3, KCNA5, KCNJ2, HCN4, PITX2, and ATRNL1, among others.
How is the atrial action potential different from the ventricular action potential?
Atrial action potentials are shorter and have a more prominent early repolarization phase due to differences in ion channel expression, such as the presence of Kv1.5 (IKur) and Kv4.3 (Ito).
What diseases are associated with abnormal atrial action potentials?
Atrial fibrillation, atrial flutter, and other atrial arrhythmias are linked to electrical remodeling of the atrial action potential.
How can I study atrial cardiac muscle cell action potentials in the lab?
Common methods include patch-clamp electrophysiology, optical mapping, and single-nuclei RNA sequencing using hiPSC-derived atrial cardiomyocytes or animal models.
What is the role of PITX2 in atrial action potentials?
PITX2 is a transcription factor that regulates ion channel and mitochondrial gene expression; its deficiency leads to mitochondrial dysfunction and increased AF susceptibility.
Can CRISPR be used to model atrial fibrillation?
Yes, CRISPR knockout, knock-in, and overexpression in hiPSC-derived atrial cardiomyocytes or mice can model AF-associated genetic variants and identify causal genes.
What is ATRNL1 and how does it relate to atrial fibrillation?
ATRNL1 is a gene identified by single-nuclei profiling as associated with atrial fibrillation; its role in atrial electrophysiology is an active area of research.
How does inflammation affect atrial action potentials?
Inflammatory mediators like IL-1β can modulate ion channel function and promote atrial fibrillation through macrophage activation and caspase-1 signaling.
What models are available for studying atrial action potentials?
hiPSC-derived atrial cardiomyocytes, heterocellular atrial engineered tissue, and genetically modified mouse models are widely used.
Conclusion
The atrial cardiac muscle cell action potential (GO:0086014) is a specialized biological process that is central to normal atrial function and the pathophysiology of atrial fibrillation. Advances in stem cell-derived atrial cardiomyocytes, single-nuclei profiling, and CRISPR-based genetic engineering have illuminated the molecular players and regulatory mechanisms underlying this process. Continued research using these tools will uncover new therapeutic targets for atrial arrhythmias and improve patient outcomes.
References
- 1. Hill MC et al.. 2024. Large-scale single-nuclei profiling identifies role for ATRNL1 in atrial fibrillation.. Nat Commun 15(1):10002 PMID: 39562555
- 2. Yamazoe M et al.. 2025. B cells promote atrial fibrillation via autoantibodies.. Nat Cardiovasc Res 4(10):1381-1396 PMID: 41062615
- 3. Seibertz F et al.. 2023. Atrial fibrillation-associated electrical remodelling in human induced pluripotent stem cell-derived atrial cardiomyocytes: a novel pathway for antiarrhythmic therapy development.. Cardiovasc Res 119(16):2623-2637 PMID: 37677054
- 4. Reyat JS et al.. 2024. PITX2 deficiency leads to atrial mitochondrial dysfunction.. Cardiovasc Res 120(15):1907-1923 PMID: 39129206
- 5. Cao Z et al.. 2025. Mitochondrial damage mediates STING activation driving obesity-mediated atrial fibrillation.. Europace 27(4) PMID: 40186485
- 6. Turner DGP et al.. 2025. Stem cell-derived heterocellular atrial engineered cardiac tissue with comparisons to native human atrial myocardium.. Am J Physiol Heart Circ Physiol 329(5):H1298-H1312 PMID: 41056371
- 7. Moreno-Loaiza O et al.. 2025. IL-1β enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression.. Nat Cardiovasc Res 4(3):312-329 PMID: 39915330
- 8. Kittaka H et al.. 2025. Active Colitis-Induced Atrial Electrophysiological Remodeling.. Biomolecules 15(7) PMID: 40723857
